胶质母细胞瘤的复发性对传统治疗策略产生了负面影响，导致对纳米药物的需求不断增长。纳米疗法是一种旨在将药物输送到特定部位的方法，正在经历快速增长并获得广泛欢迎。该领域具有到达难以到达的疾病部位的潜力，有可能在对抗胶质母细胞瘤进展方面表现出高效能。胶质母细胞瘤干细胞（GSC）的存在是多形性胶质母细胞瘤（GBM）预后不良的一个主要因素。干细胞潜力、异质性和自我更新能力是使 GSC 侵入大脑较远区域的一些特性。尽管医疗技术和 MRI 引导下的最大手术切除取得了进步，但并非所有存在于大脑中的 GSC 都可以被切除，从而导致疾病复发。 GBM 的侵袭性通常与免疫抑制相关，即 T 细胞无法浸润癌症引发的 GSC。标准护理疗法，包括手术和化疗联合放射治疗，未能解决 GSC 的所有挑战，因此研究人员制定解决其生长和增殖并减少 GBM 复发的策略变得越来越重要。在这里，我们将重点关注纳米医学领域的进展，这些进展有可能对管理胶质母细胞瘤肿瘤微环境产生积极影响。本文分类为：治疗方法和药物发现 > 肿瘤疾病纳米医学。© 2024 作者。 WIREs 纳米医学和纳米生物技术由 Wiley periodicals LLC 出版。

The recurrent nature of glioblastoma negatively impacts conventional treatment strategies leading to a growing need for nanomedicine. Nanotherapeutics, an approach designed to deliver drugs to specific sites, is experiencing rapid growth and gaining immense popularity. Having potential in reaching the hard-to-reach disease sites, this field has the potential to show high efficacy in combatting glioblastoma progression. The presence of glioblastoma stem cells (GSCs) is a major factor behind the poor prognosis of glioblastoma multiforme (GBM). Stemness potential, heterogeneity, and self-renewal capacity, are some of the properties that make GSCs invade across the distant regions of the brain. Despite advances in medical technology and MRI-guided maximal surgical resection, not all GSCs residing in the brain can be removed, leading to recurrent disease. The aggressiveness of GBM is often correlated with immune suppression, where the T-cells are unable to infiltrate the cancer initiating GSCs. Standard of care therapies, including surgery and chemotherapy in combination with radiation therapy, have failed to tackle all the challenges of the GSCs, making it increasingly important for researchers to develop strategies to tackle their growth and proliferation and reduce the recurrence of GBM. Here, we will focus on the advancements in the field of nanomedicine that has the potential to show positive impact in managing glioblastoma tumor microenvironment. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.© 2024 The Author(s). WIREs Nanomedicine and Nanobiotechnology published by Wiley Periodicals LLC.